Customizable and consistent dosing for your patients with no titration required
Consistency
Steady infusion rate, customizable from the start1
Confidence
Favorable tolerability and safety profile1
Reassurance
Tailored dosing schedule1
SCIG therapy with customizable dosing up to 25 mL/hr/site from the start1
- Tailor the dosing schedule to meet your patients’ individual needs and preferred infusion schedules
- HCPs and patients choose the number of infusion sites from 1 to 6
- Most infusions in the study were conducted using 2 or 4 sites (30.5% and 56.2% of total infusions, respectively)2
Patients receiving XEMBIFY can start and stay at the same infusion rate1
Infusion rate: up to 25 mL/hr/site from the start of treatment
Number of sites: up to 6
Site distance: more than 2 inches apart
No titration required
- Children will likely require less total volume for a specific XEMBIFY dose (mg/kg body weight) than adults
- The healthcare provider may choose a smaller volume/site for children and/or fewer infusion sites to achieve the target total dose, depending on the needs of the child
XEMBIFY offers patients with PIDD flexibility and options
Convenient handling and storage1
- No refrigeration needed for up to 6 months*
- Check the lot number, expiration date, tamper-evident seal, color and clarity, and storage temperature before infusion of XEMBIFY
- Never shake XEMBIFY
- Available in 1 g, 2 g, 4 g, and 10 g single-use vials*
*XEMBIFY may be stored for 36 months at 2-8 °C (36-46 °F) from the date of manufacture and the product may be stored at temperatures not to exceed 25 °C (77 °F) for up to 6 months any time prior to the expiration date. Following 25 °C (77 °F) storage, use the product immediately or discard. Do not freeze.1
Not actual size
XEMBIFY self-infusion instructional video
This video demonstrates step-by-step instructions for self-infusing XEMBIFY for patients with PIDD.
Administration Guide
Get the full details on XEMBIFY dosing and administration
Prescription Referral Form
Remember “Dispense as Written” to get your patients started on XEMBIFY
Treatment with XEMBIFY can benefit a range of patients
Example patients starting treatment with XEMBIFY
43 years old, 110 lb (50 kg)
Ashley
Ashley is a sixth-grade schoolteacher who is married with 2 children and has been diagnosed with CVID. She has poorly controlled asthma and a history of migraine. Ashley recently started antibiotic therapy due to chronic sinusitis and multiple episodes of bacterial pneumonia. She wants to discontinue IVIG treatment due to severe headaches. She needs an IG treatment like XEMBIFY that has a low incidence of headaches.
Ashley’s customized dosing schedule*:
Dosing frequency and interval: once weekly
Weekly XEMBIFY dose: 10 g (50 mL)†
Number of infusion sites: 3
Infusion rate: 20 mL/hr/site
Infusion time: ~1 hour, depending on regulator used
Not an actual patient
14 years old, 121 lb (55 kg)
Jenna
Jenna is a 14-year-old freshman in high school with CVID. She loves sports and hanging out with her friends. She experiences lethargy and malaise before her next dose of IVIG, consistent with “wear-off” effect.
Jenna's customized dosing schedule*:
Dosing frequency and interval: once weekly
Weekly XEMBIFY dose: 10 g (50 mL)†
Number of infusion sites: 2
Infusion rate: 25 mL/hr/site
Infusion time: ~1 hour, depending on regulator used
Not an actual patient
6 years old, 24 lb (11 kg)
Hayden
Hayden is a happy and active 6-year-old boy. He attends school 5 days a week and enjoys sharing toys and playing with his friends. Since he was 6 months old, Hayden has suffered from recurrent otitis and chronic cough. Hayden’s physician has confirmed diagnosis of PIDD.
Hayden’s customized dosing schedule*:
Dosing frequency and interval: once weekly
Weekly XEMBIFY dose: weekly alternating XEMBIFY dose of 1 g (5 mL) and 2 g (10 mL), respectively†
Number of infusion sites: 1
Infusion rate: 5 mL/hr/site
Infusion time: ~1-2 hours, depending on regulator used
Not an actual patient
*To convert the XEMBIFY dose in grams to milliliters (mL), multiply the calculated initial SCIG dose in grams by 5.
†Initial weekly dose of SCIG in grams = prior IVIG in grams/number of weeks between IVIG doses x 1.37.
See the demonstrated safety and tolerability for XEMBIFY
Review how to start your patients on treatment with XEMBIFY
Get your patients enrolled in Xembify ConnexionsTM
Find out more about XEMBIFY—speak to a Sales Representative, Nurse Educator, or Medical Science Liaison.
Indication
XEMBIFY® (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. XEMBIFY is for subcutaneous administration only.
Important Safety Information
WARNING: THROMBOSIS
- Thrombosis may occur with immune globulin products, including XEMBIFY. Risk factors may include: advanced age, prolonged immobilization, estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors
- For patients at risk of thrombosis, administer XEMBIFY at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity
Contraindications
XEMBIFY is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
Warnings and Precautions
Hypersensitivity. Severe hypersensitivity reactions may occur with immune globulin products, including XEMBIFY. In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. XEMBIFY contains IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.
Thrombosis. Thrombosis may occur following treatment with immune globulin products, including XEMBIFY. Thrombosis may occur in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
Aseptic meningitis syndrome (AMS). AMS may occur with human immune globulin treatment, including XEMBIFY. Conduct a thorough neurological exam on patients exhibiting signs and symptoms to rule out other causes of meningitis. Discontinuation of treatment has resulted in remission within several days without sequelae.
Renal dysfunction/failure. Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin products, especially those containing sucrose. XEMBIFY does not contain sucrose. Ensure patients are not volume-depleted prior to starting infusion. In patients at risk due to preexisting renal insufficiency or predisposition to acute renal failure, assess renal function prior to the initial infusion of XEMBIFY and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation.
Hemolysis. XEMBIFY may contain blood group antibodies that may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for clinical signs and symptoms of hemolysis. If signs and symptoms are present after infusion, perform confirmatory lab testing.
Transfusion-related acute lung injury (TRALI). Noncardiogenic pulmonary edema may occur in patients following treatment with immune globulin products, including XEMBIFY. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of antineutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support.
Transmissible infectious agents. Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD, or CJD have ever been associated with the use of XEMBIFY.
Interference with lab tests. After infusion of XEMBIFY, passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation.
Adverse Reactions
The most common adverse reactions in ≥ 5% of subjects in the clinical trial were local adverse reactions, including infusion-site erythema (redness), infusion-site pain, infusion-site swelling (puffiness), infusion-site bruising, infusion-site nodule, infusion-site pruritus (itching), infusion-site induration (firmness), infusion-site scab, infusion-site edema, and systemic reactions including cough and diarrhea.
Drug Interactions
Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (eg, measles, mumps, rubella, and varicella).
Please see accompanying full Prescribing Information for XEMBIFY.
Terms to know
CVID, common variable immunodeficiency; IG, immune globulin; IVIG, intravenous immunoglobulin; PIDD, primary immunodeficiency disease; SCIG, subcutaneous immunoglobulin.
References
- XEMBIFY® (immune globulin subcutaneous human-klhw) 20% Prescribing Information. Grifols.
- Sleasman JW, Lumry WR, Hussain I, et al. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, phase III study. Immunotherapy. 2019;11(16):1371-1386.